Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Weise, David
ADOPTION, NCT04990284 / 2020-002754-24: eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	Active, not recruiting	4	106	Europe	Opicapone, BIA 9-1067, L-DOPA/DDCI, Levodopa	Bial - Portela C S.A., Bial - Portela & Ca, S.A.	Parkinson Disease	06/23	06/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29